Search results for Ieramilimab
Ieramilimab Biosimilar – Anti-LAG3 mAb – Research Grade, ProteoGenix, PX-TA1562
Description of Ieramilimab Biosimilar - Anti-LAG3 mAb - Research Grade Introduction: Ieramilimab Biosimilar, also known as Anti-LAG3 mAb, is a research grade monoclonal antibody that has shown promising results in pre-clinical studies as a potential therapeutic target for various diseases. This article will provide a detailed description of the structure, activity, and potential applications of Ieramilimab Biosimilar in the field of immunotherapy. Structure of Ieramilimab Biosimilar: Ieramilimab Biosimilar is a humanized monoclonal antibody that targets the lymphocyte activation gene 3 (LAG3) protein. It is composed of two identical heavy chains and two identical light chains, each containing a variable and constant region. The variable region of the antibody is responsible for binding to the LAG3 protein, while the constant region determines the effector function of the antibody. Activity of Ieramilimab Biosimilar: LAG3 is a cell surface protein that is primarily expressed on activated T cells and natural killer (NK) cells. It plays a crucial role in regulating immune responses by inhibiting the activation and proliferation of T cells. However, in certain diseases, such as cancer and autoimmune disorders, LAG3 expression is upregulated, leading to immune suppression and disease progression. Ieramilimab Biosimilar works by binding to LAG3 and blocking its inhibitory function, thereby promoting immune responses against cancer cells or reducing autoimmunity. Potential Applications of Ieramilimab Biosimilar: 1. Cancer Immunotherapy: One of the most promising applications of Ieramilimab Biosimilar is in the field of cancer immunotherapy. By targeting LAG3, this antibody can enhance the anti-tumor immune response and potentially improve the efficacy of other cancer therapies. Pre-clinical studies have shown that Ieramilimab Biosimilar can inhibit tumor growth and improve survival rates in various cancer models, including melanoma, lung cancer, and breast cancer. 2. Autoimmune Disorders: Autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, are characterized by an overactive immune response against the body’s own tissues. LAG3 is known to play a role in the development and progression of these diseases. By blocking LAG3, Ieramilimab Biosimilar can potentially reduce the activity of autoreactive T cells and alleviate symptoms of autoimmune disorders. 3. Infectious Diseases: LAG3 has also been implicated in the immune response against certain infectious diseases, such as HIV and tuberculosis. Pre-clinical studies have shown that Ieramilimab Biosimilar can enhance the immune response against these pathogens and potentially improve the efficacy of current treatments. 4. Combination Therapy: Due to its unique mechanism of action, Ieramilimab Biosimilar has the potential to be used in combination with other immunotherapies, such as checkpoint inhibitors and CAR T cell therapy. This combination approach can potentially enhance the anti-tumor immune response and improve treatment outcomes for cancer patients. Conclusion: In conclusion, Ieramilimab Biosimilar is a promising research grade monoclonal antibody that targets LAG3 and has shown potential in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. Its unique mechanism of action and potential for combination therapy make it an exciting candidate for further development in the field of immunotherapy. Further clinical studies are needed to fully explore the potential of Ieramilimab Biosimilar and its role in the treatment of these diseases.
Host
Reactivity
Applications
Conjugation
Ieramilimab, Abbexa, abx831521
Ieramilimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting LAG3, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Leramilimab of Novartis, an antibody drug targeting LAG3.
Host
Human
Reactivity
Human
Applications
ELISA, WB
Conjugation
Unconjugated
Ieramilimab ELISA Kit, ProteoGenix, KPTX202
Description of Ieramilimab ELISA Kit Introduction The Ieramilimab ELISA Kit is a highly sensitive and specific tool for the detection and quantification of Ieramilimab, a novel antibody targeting a specific therapeutic target. This kit is designed for use in scientific research and drug development, providing valuable insights into the structure, activity, and potential applications of this promising therapeutic agent. Structure of Ieramilimab Ieramilimab, also known as TAK-659, is a humanized monoclonal antibody that specifically binds to the protein Spleen Tyrosine Kinase (SYK). SYK is a key signaling molecule involved in the activation of immune cells, making it an attractive therapeutic target for various autoimmune and inflammatory diseases. The Ieramilimab antibody consists of two heavy chains and two light chains, with a total molecular weight of approximately 150 kDa. It has a unique structure that allows it to bind specifically to SYK, inhibiting its activity and modulating the immune response. Activity of Ieramilimab The primary mechanism of action of Ieramilimab is the inhibition of SYK, which is involved in the activation of immune cells such as B-cells, T-cells, and mast cells. By binding to SYK, Ieramilimab prevents downstream signaling and activation of these cells, resulting in a reduction of inflammation and immune response. In addition to its inhibitory effects on immune cells, Ieramilimab has also been shown to induce apoptosis (cell death) in cancer cells that overexpress SYK. This makes it a promising therapeutic agent for the treatment of certain types of cancer, such as B-cell lymphomas and leukemias. Application of Ieramilimab The Ieramilimab ELISA Kit has a wide range of potential applications in scientific research and drug development. Some of the key applications include: 1. Evaluation of Ieramilimab levels in biological samples The ELISA Kit allows for the accurate and quantitative measurement of Ieramilimab levels in various biological samples, such as serum, plasma, and cell culture supernatants. This is essential for monitoring the pharmacokinetics and pharmacodynamics of Ieramilimab in preclinical and clinical studies. 2. Screening of potential therapeutic targets The Ieramilimab ELISA Kit can also be used to screen for potential therapeutic targets involved in the SYK signaling pathway. By measuring the levels of Ieramilimab in the presence of different targets, researchers can identify new targets for drug development and gain a better understanding of the mechanism of action of Ieramilimab. 3. Preclinical and clinical studies The accurate and sensitive measurement of Ieramilimab levels provided by the ELISA Kit is crucial for the successful development of this therapeutic agent. It can be used to determine the optimal dosing regimen, evaluate the efficacy of Ieramilimab in preclinical and clinical studies, and monitor patient response to treatment. 4. Biomarker discovery The Ieramilimab ELISA Kit can also be used to identify potential biomarkers associated with SYK signaling and Ieramilimab treatment. This can provide valuable insights into the mechanism of action of Ieramilimab and aid in the development of personalized treatment strategies. Conclusion The Ieramilimab ELISA Kit is a powerful tool for the detection and quantification of this novel therapeutic antibody. Its high sensitivity and specificity make it an essential tool for researchers and drug developers interested in understanding the structure, activity, and potential applications of Ieramilimab in various diseases. With its wide range of potential applications, this kit is an invaluable resource for advancing the development of Ieramilimab as a promising therapeutic agent.
Host
Reactivity
Applications
Conjugation
Ieramilimab ELISA Kit, Abbexa, abx395091
Ieramilimab ELISA Kit is a quantitative ELISA kit for detection of Ieramilimab.Ieramilimab (LAG525) is a humanized immunoglobulin 4 (IgG4) (S228P) mAb that binds to LAG-3, resulting in inhibition of LAG-3 interaction with MHC-II molecules
Host
Reactivity
Human
Applications
ELISA
Conjugation
Ieramilimab Biosimilar - Research Grade, ichor.bio, ICH5098
Detects human LAG3
Host
CHO Cells
Reactivity
Human
Applications
Conjugation
Please provide the required information below so that we can quickly source your products.